Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata | Zendy

Nathan P. Wiederhold | Zendy; Laura K. Najvar | Zendy; Rosie Jaramillo | Zendy; Marcos Olivo | Zendy; Jason Pizzini | Zendy; Gabriel Catano | Zendy; Thomas F. Patterson | Zendy

Open Access

Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata

Author(s) -

Nathan P. Wiederhold,

Laura K. Najvar,

Rosie Jaramillo,

Marcos Olivo,

Jason Pizzini,

Gabriel Catano,

Thomas F. Patterson

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx422

Subject(s) - echinocandin , caspofungin , echinocandins , candida glabrata , microbiology and biotechnology , pharmacology , in vivo , biology , medicine , amphotericin b , candida albicans , antifungal , fluconazole

Echinocandins are recommended as first-line therapy against Candida glabrata infections, although increased resistance to this class has been reported worldwide and they are currently only available for parenteral administration. SCY-078 is an investigational glucan synthase inhibitor that is orally available.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research